News | May 20, 2013

Dual Chamber Defibrillators Pose Higher Risk of Complications

May 20, 2013 — A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death by detecting irregularities and delivering an electrical jolt to restart the heart.

An analysis led by researchers at University of Colorado School of Medicine and published in the May 15 issue of The Journal of the American Medical Association focused on people getting ICDs who do not have a clear reason for pacemaker support. The study found more complex and more expensive dual-chamber ICDs do not appear to offer any clinical benefit when compared with single-chamber devices. In fact, dual chamber devices were associated with more complications in the first year after implantation.

“A central decision regarding ICD therapy is whether to use a single-chamber or dual-chamber device,” says the study’s lead author, Pamela Peterson, M.D., MSPH, associate professor of medicine in the division of cardiology at the CU School of Medicine. “More complex dual-chamber devices may offer theoretical benefits but may also have greater risks.”

Peterson and colleagues compared outcomes, including mortality, hospitalizations and longer-term device related complications between single- and dual-chamber devices. The study included admissions in the National Cardiovascular Data Registry’s (NCDR) ICD registry from 2006-2009 that could be linked to Centers for Medicare & Medicaid Services data. 

Among 32,034 patients, 12,246 (38 percent) received a single-chamber device and 19,788 (62 percent) received a dual-chamber device. Rates of complications were lower for single-chamber devices (3.51 percent vs. 4.72 percent), but there was no difference between patients receiving single lead or dual lead devices with respect to one-year mortality (unadjusted rate, 9.85 percent vs. 9.77 percent), one-year all-cause hospitalization (unadjusted rate, 43.86 percent vs. 44.83 percent), or hospitalization for heart failure (unadjusted rate, 14.73 percent vs. 15.38 percent).

 “Because implanting a dual-chamber ICD is a more complex and time-consuming procedure than implanting a single-chamber device, the possibility of device-related complications such as infection and lead displacement are higher,” Peterson says. “The decision to implant a dual-chamber ICD should be considered carefully.”

Peterson’s work is supported by a grant from the Agency for Healthcare Research and Quality. This research also was supported by the American College of Cardiology Foundation’s National Cardiovascular Data Registry (NCDR).


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now